Skip to content
2000
Volume 20, Issue 3
  • ISSN: 2772-4344
  • E-ISSN: 2772-4352

Abstract

Background

is a common cause of healthcare-associated infections such as Pneumonia, Bloodstream, Urinary tract, and Surgical site infections this bacterium is also reported to cause infections in cancerous cells. It is one of the most considered opportunistic human pathogens, especially in immunocompromised patients, and one of the top five pathogens of nosocomial diseases worldwide. Some are becoming more resistant to even antibiotics of last resort, including beta-lactams, fluoroquinolones, tetracycline, chloramphenicol, macrolides, and aminoglycosides, and are described as multidrug-resistant. Multiple lines of evidence suggest that the chief mechanism for resistance to antibiotics regulated by the efflux pumps. Antibiotic efflux pumps are membrane proteins that actively remove antibiotics from the bacterial cell, lowering on-target antibiotic concentrations to sub-toxic levels. The MexAB-OprM system is one of the largest multi-drug resistant clinically relevant efflux pumps with high expression levels in . Inhibition of these MDR efflux pumps can restore the activity of antimicrobial agents that are substrates for this protein. We performed molecular modelling studies in this study to discover novel Mex B efflux pump inhibitors. We evaluated the MIC of α-Bisabolol and Meropenem combination against Meropenem-resistant strains. This research opened up the possibility of using this plant compound α-Bisabolol and resistance drug Meropenem combination in the development of medicines for human consumption, possibly for the treatment of Hospital-Acquired Pneumonia, and multidrug-resisting infection caused by including wound and urinary infections which have been reported important HAI carbapenem class multidrug infections caused by the bacteria.

Methods

The present study investigates the interactions of plant secondary metabolites tables on Mex B efflux protein. It identifies lead molecules for developing adjuvants against efflux-mediated multidrug resistance in infections, enhances antibiotic activity against MDR pathogens, and evaluates the MIC value of the test plant compound (Bisabolol) and the resistant antibiotic (Meropenem).

Results

Among plant compounds, α-Bisabolol, myricetin, capsaicin, equenin, aloe-emodin, terpinene, fisetin, taxifolin, catechin, and galangin showed G-Scorehigher than -7 kcal/mol, and interact with active amino acids Mex B efflux protein which may affect the efflux transport of drug and enhance the antibiotic activity against MDR infection. According to docking experiments, α-bisabolol has a higher affinity energy to the MexB protein than Meropenem. Furthermore, α-bisabolol binds to the MexB binding site hydrophobic trap region of MexB, which may cause a conformational change in the transporter's pumping process, thereby affecting antibiotic efflux inhibition. The MICs against Meropenem were 12.5 µg/ml for antibiotic Meropenem and 6.24 μg/ml for the combination.

Conclusion

The study concluded that these plant secondary metabolite compounds could be used to develop adjuvant along with antibiotics to increase their activity against MexAB-OprM efflux-mediated multidrug-resisting infections. It was determined that α-bisabolol may have the potential to boost antibacterial activity when combined with antibiotics, as well as being a strong candidate for an efflux pump inhibitor. This is the first inclusion of the properties of a natural plant phytochemical, Bisabolol, utilized in combination with commercial resistant antibiotic Meropenem to enhance its activity against MDR pneumonia infection caused by .

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raaidd/10.2174/0127724344343717250404114236
2025-04-21
2025-12-15

  • From This Site

    /content/journals/raaidd/10.2174/0127724344343717250404114236
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CompagneN. Vieira Da CruzA. MüllerR.T. HartkoornR.C. FlipoM. PosK.M. Update on the discovery of efflux pump inhibitors against critical priority gram-negative bacteria.Antibiotics202312118010.3390/antibiotics12010180
     [Google Scholar]
  2. SamreenF.A.Q. QaisF.A. AhmadI. In silico screening and in vitro validation of phytocompounds as multidrug efflux pump inhibitor against E. coli.J. Biomol. Struct. Dyn.20234162189220110.1080/07391102.2022.2029564 35067192
     [Google Scholar]
  3. BotelhoJ. GrossoF. PeixeL. Antibiotic resistance in Pseudomonas aeruginosa – Mechanisms, epidemiology and evolution.Drug Resist. Updat.20194410064010.1016/j.drup.2019.07.002 31492517
     [Google Scholar]
  4. TsutsumiK. YoneharaR. Ishizaka-IkedaE. Structures of the wild-type MexAB–OprM tripartite pump reveal its complex formation and drug efflux mechanism.Nat. Commun.2019101152010.1038/s41467‑019‑09463‑9 30944318
     [Google Scholar]
  5. BehzadiP. AmbrosiC. ScribanoD. Editorial: Current perspectives on Pseudomonas aeruginosa: Epidemiology, virulence and contemporary strategies to combat multidrug-resistant (MDR) pathogens.Front. Microbiol.202297561610.3389/fmicb.2022.975616
     [Google Scholar]
  6. AlenazyR. Drug efflux pump inhibitors: A promising approach to counter multidrug resistance in gram-negative pathogens by targeting AcrB protein from AcrAB-TolC multidrug efflux Pump from Escherichia coli.Biology2022119132810.3390/biology11091328
     [Google Scholar]
  7. OppermanT.J. NguyenS.T. Recent advances toward a molecular mechanism of efflux pump inhibition.Front. Microbiol.201542110.3389/fmicb.2015.00421
     [Google Scholar]
  8. PanY. XuY. WangZ. FangY. ShenJ. Overexpression of MexAB-OprM efflux pump in carbapenem-resistant Pseudomonas aeruginosa.Arch. Microbiol.2016198656557110.1007/s00203‑016‑1215‑7 27060003
     [Google Scholar]
  9. NaritaS. TokudaH. Amino acids at positions 3 and 4 determine the membrane specificity of Pseudomonas aeruginosa lipoproteins.J. Biol. Chem.200728218133721337810.1074/jbc.M611839200 17350956
     [Google Scholar]
  10. NanjanP. BoseV. Efflux-mediated multidrug resistance in critical gram-negative bacteria and natural efflux pump inhibitors.Curr. Drug Res. Rev.202416334936810.2174/0125899775271214240112071830 38288795
     [Google Scholar]
  11. DiasK.J.S.O. MirandaG.M. BessaJ.R. Terpenes as bacterial efflux pump inhibitors: A systematic review.Front. Pharmacol.20221395398210.3389/fphar.2022.953982
     [Google Scholar]
  12. MahizanN.A. YangS.K. MooC.L. Terpene derivatives as a potential agent against antimicrobial resistance (AMR) pathogens.Molecules20192414263110.3390/molecules24142631
     [Google Scholar]
  13. SeukepA.J. KueteV. NaharL. SarkerS.D. GuoM. Plant-derived secondary metabolites as the main source of efflux pump inhibitors and methods for identification.J. Pharm. Anal.202010427729010.1016/j.jpha.2019.11.002 32923005
     [Google Scholar]
  14. ColluF. VargiuA.V. DreierJ. CascellaM. RuggeroneP. Recognition of imipenem and meropenem by the RND-transporter MexB studied by computer simulations.J. Am. Chem. Soc.201213446191461915810.1021/ja307803m 23146101
     [Google Scholar]
  15. VargiuA.V. Water-mediated interactions enable smooth substrate transport in a bacterial efflux pump.Biochim. Biophys. Acta, Gen. Subj.20181862483684510.1016/j.bbagen.2018.01.010
     [Google Scholar]
  16. GlavierM. PuvanendranD. SalvadorD. Antibiotic export by MexB multidrug efflux transporter is allosterically controlled by a MexA-OprM chaperone-like complex.Nat. Commun.2020111494810.1038/s41467‑020‑18770‑5 33009415
     [Google Scholar]
  17. SuC.C. LiM. GuR. Conformation of the AcrB multidrug efflux pump in mutants of the putative proton relay pathway.J. Bacteriol.2006188207290729610.1128/JB.00684‑06 17015668
     [Google Scholar]
  18. AlavI. KobylkaJ. KuthM.S. Structure, assembly, and function of tripartite efflux and type 1 secretion systems in gram-negative bacteria.Chem. Rev.202112195479559610.1021/acs.chemrev.1c00055 33909410
     [Google Scholar]
  19. TakatsukaY. ChenC. NikaidoH. Mechanism of recognition of compounds of diverse structures by the multidrug efflux pump AcrB of Escherichia coli.Proc. Natl. Acad. Sci. USA2010107156559656510.1073/pnas.1001460107 20212112
     [Google Scholar]
  20. AronZ. OppermanT.J. Optimization of a novel series of pyranopyridine RND efflux pump inhibitors.Curr. Opin. Microbiol.2016331610.1016/j.mib.2016.05.007 27232955
     [Google Scholar]
  21. AronZ. OppermanT.J. The hydrophobic trap—the Achilles heel of RND efflux pumps.Res. Microbiol.20181697-839340010.1016/j.resmic.2017.11.001 29146106
     [Google Scholar]
  22. AparnaV. DineshkumarK. MohanalakshmiN. VelmuruganD. HopperW. Identification of natural compound inhibitors for multidrug efflux pumps of Escherichia coli and Pseudomonas aeruginosa using in silico high-throughput virtual screening and in vitro validation.PLoS One201497e10184010.1371/journal.pone.0101840
     [Google Scholar]
  23. GervasoniS. MehlaJ. BergenC.R. Molecular determinants of avoidance and inhibition of Pseudomonas aeruginosa MexB efflux pump.MBio2023144e01403e0142310.1128/mbio.01403‑23 37493633
     [Google Scholar]
  24. ZgurskayaH.I. Bacterial efflux transporters’ polyspecificity - A gift and a curse?Curr. Opin. Microbiol.20216111512310.1016/j.mib.2021.03.009
     [Google Scholar]
  25. AtharM. GervasoniS. CatteA. Tripartite efflux pumps of the RND superfamily: What did we learn from computational studies?Microbiology2023169300130710.1099/mic.0.001307 36972322
     [Google Scholar]
  26. Ferrer-EspadaR. ShahrourH. PittsB. StewartP.S. Sánchez-GómezS. Martínez-de-TejadaG. A permeability-increasing drug synergizes with bacterial efflux pump inhibitors and restores susceptibility to antibiotics in multi-drug resistant Pseudomonas aeruginosa strains.Sci. Rep.201991345210.1038/s41598‑019‑39659‑4 30837499
     [Google Scholar]
  27. AvakhA. GrantG.D. CheesmanM.J. KalkundriT. HallS. The art of war with Pseudomonas aeruginosa: Targeting mex efflux pumps directly to strategically enhance antipseudomonal drug efficacy.Antibiotics2023128130410.3390/antibiotics12081304 37627724
     [Google Scholar]
  28. BurleyS.K. BhikadiyaC. BiC. RCSB Protein Data Bank: Powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences.Nucleic Acids Res.202149D1D437D45110.1093/nar/gkaa1038 33211854
     [Google Scholar]
  29. XiaX. Bioinformatics and drug discovery.Curr. Top. Med. Chem.201717151709172610.2174/1568026617666161116143440 27848897
     [Google Scholar]
  30. VijayakumarS. ManogarP. PrabhuS. SanjeevkumarS.R.A. Novel ligand-based docking; molecular dynamic simulations; and absorption, distribution, metabolism, and excretion approach to analyzing potential acetylcholinesterase inhibitors for Alzheimer’s disease.J. Pharm. Anal.20188641342010.1016/j.jpha.2017.07.006 30595949
     [Google Scholar]
  31. SinhaS. PatelS. AtharM. Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: An in silico and in vitro study.Int. J. Biol. Macromol.201914045446810.1016/j.ijbiomac.2019.08.061 31404596
     [Google Scholar]
  32. HashemH.E. In silico approach of some selected honey constituents as SARS-CoV-2 main protease (COVID-19) inhibitors.Eur J Med Oncol20204319620010.14744/ejmo.2020.36102
     [Google Scholar]
  33. MohantyM. MohantyP.S. Molecular docking in organic, inorganic, and hybrid systems: A tutorial review.Monatsh. Chem.2023154768370710.1007/s00706‑023‑03076‑1 37361694
     [Google Scholar]
  34. HatamiS. SirousH. MahnamK. NajafipourA. FassihiA. Preparing a database of corrected protein structures important in cell signaling pathways.Res. Pharm. Sci.2023181677810.4103/1735‑5362.363597 36846730
     [Google Scholar]
  35. RoltaR. SalariaD. KumarV. Molecular docking studies of phytocompounds of Rheum emodi Wall with proteins responsible for antibiotic resistance in bacterial and fungal pathogens: In silico approach to enhance the bio-availability of antibiotics.J. Biomol. Struct. Dyn.20224083789380310.1080/07391102.2020.1850364 33225862
     [Google Scholar]
  36. NurhanA.D. GaniM.A. MaulanaS. SiswodihardjoS. ArdiantoC. KhotibJ. Molecular docking studies for protein-targeted drug development in SARS-CoV-2.Lett. Drug Des. Discov.202219542843910.2174/1570180818666210512021619
     [Google Scholar]
  37. ShahB. ModiP. SagarS.R. In silico studies on therapeutic agents for COVID-19: Drug repurposing approach.Life Sci.202025211765210.1016/j.lfs.2020.117652 32278693
     [Google Scholar]
  38. RoltaR. YadavR. SalariaD. In silico screening of hundred phytocompounds of ten medicinal plants as potential inhibitors of nucleocapsid phosphoprotein of COVID-19: An approach to prevent virus assembly.J. Biomol. Struct. Dyn.202139187017703410.1080/07391102.2020.1804457 32851912
     [Google Scholar]
  39. YusofI. SegallM.D. Considering the impact drug-like properties have on the chance of success.Drug Discov. Today20131813-1465966610.1016/j.drudis.2013.02.008 23458995
     [Google Scholar]
  40. FilimonovD.A. LaguninA.A. GloriozovaT.A. Prediction of the biological activity spectra of organic compounds using the pass online web resource.Chem. Heterocycl. Compd.201450344445710.1007/s10593‑014‑1496‑1
     [Google Scholar]
  41. AminM.R. YasminF. HosenM.A. Synthesis, antimicrobial, anticancer, PASS, molecular docking, molecular dynamic simulations & pharmacokinetic predictions of some Methyl β-D-Galactopyranoside analogs.Molecules20212622701610.3390/molecules26227016 34834107
     [Google Scholar]
  42. ChughA. SehgalI. KhuranaN. Comparative docking studies of drugs and phytocompounds for emerging variants of SARS-CoV-2.BioTech20231313610.1007/s13205‑022‑03450‑6
     [Google Scholar]
  43. MohsR.C. GreigN.H. Drug discovery and development: Role of basic biological research.Alzheimers Dement.20173465165710.1016/j.trci.2017.10.005
     [Google Scholar]
  44. ZhouY. HouZ. FangC. Comparison of microplate and macrodilution methods in time–kill study of new antimicrobial drugs.Folia Microbiol.201358191610.1007/s12223‑012‑0168‑8 22684972
     [Google Scholar]
  45. AhmedS. ShohaelA.M. In-silico studies of four anthraquinones of Senna alata L. as potential antifungal compounds.Pharmacology20192259268
     [Google Scholar]
/content/journals/raaidd/10.2174/0127724344343717250404114236
Loading
In silico Screening of Plant Compounds to Inhibit MexB Efflux Protein for the Enhancement of Meropenem Resistance against Pseudomonas aeruginosa MDR Infections
Recent Adv Antiinfect Drug Discov 20, 223 (2025); https://doi.org/10.2174/0127724344343717250404114236
/content/journals/raaidd/10.2174/0127724344343717250404114236
/content/journals/raaidd/10.2174/0127724344343717250404114236
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): antibiotic efflux pumps; in silico screening of plant compounds; MexAB-OprM; multidrug resistance; novel mex B efflux pump inhibitors; Pseudomonas aeruginosa

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test